DexCom Inc (DXCM)vsNeuropace Inc (NPCE)
DXCM
DexCom Inc
$83.03
-1.75%
HEALTHCARE · Cap: $31.90B
NPCE
Neuropace Inc
$14.04
+1.23%
HEALTHCARE · Cap: $511.43M
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 4544% more annual revenue ($4.97B vs $106.99M). DXCM leads profitability with a 20.1% profit margin vs -17.9%. DXCM earns a higher WallStSmart Score of 74/100 (B).
DXCM
Strong Buy74
out of 100
Grade: B
NPCE
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DXCM.
Margin of Safety
-17.2%
Fair Value
$12.42
Current Price
$14.04
$1.62 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 38 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
17.1% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Trading at 11.9x book value
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 40.1x book value
ROE of -160.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bull Case : NPCE
The strongest argument for NPCE centers on Revenue Growth. Revenue growth of 17.1% demonstrates continued momentum.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Bear Case : NPCE
The primary concerns for NPCE are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 5.88 is elevated, increasing financial risk.
Key Dynamics to Monitor
DXCM profiles as a mature stock while NPCE is a growth play — different risk/reward profiles.
NPCE carries more volatility with a beta of 1.95 — expect wider price swings.
NPCE is growing revenue faster at 17.1% — sustainability is the question.
DXCM generates stronger free cash flow (185M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (74/100 vs 27/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Neuropace Inc
HEALTHCARE · MEDICAL DEVICES · USA
NeuroPace, Inc. is a medical device company in the United States. The company is headquartered in Mountain View, California.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?